drugset / Trial / NCT07449286
IFN-α in Relapse Prevention.
Phase 2
Not yet recruiting
100 enrolled
Peking University People's Hospital
Aerospace Medical Center · collabLU DAOPEI MEDICAL · collabNanfang Hospital, Southern Medical University · collabZhejiang University · collab
NaSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Timeline
- Start
- 2026-03-01
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IFN-α | Unknown | 3e+06 iu | Subcutaneous |